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There were two parts to the study: a registration/induction chemotherapy period, and a subsequent randomization. After routine staging by bone, liver, and brain imaging and bone marrow sampling, patients with limited stage disease were registered with the LCSG operations office and were given the following: cyclophosphamide, 1 g/m2; doxorubicin, 50 mg/m2; and vincristine, 1.4 mg/m2 every 3 weeks for five cycles. Objective responders who fulfilled eligibility criteria (listed below) were restaged clinically and then were randomized either to undergo thoracotomy and attempted pulmonary resection followed by chest and brain irradiation or to receive the radiotherapy without having had surgery.
The radiation therapy doses were 50 Gy in 25 fractions to the chest, the target being the initial (prechemotherapy) tumor volume and mediastinum, and 30 Gy in 15 fractions whole brain prophylaxis. Brain and chest irradiation were delivered concurrently. The only variable in the scheme is the surgical treatment.
The goals of thoracotomy were to remove the primary site and all gross mediastinal disease and to stage the mediastinum. In the event of a complete remission, the lobe of initial tumor involvement, documented by endoscopic diagram at the time of diagnosis, was removed, including pneumonectomy for central primary lesions. All patients undergoing surgery were to have node samples taken from at least paratracheal (ATS 2 or 4), subcarinal (ATS 7), hilar (ATS 10), and intrapulmonary (ATS 11 to 13) nodal stations during mediastinal node dissection, whether or not there was grossly visible tumor involvement in these areas. Eligibility criteria were different for each of the two periods of the study. It was sufficient for registration to have limited stage disease and to be in good general health. Limited stage was defined for the purposes of this study to exclude supraclavicular lymph node metastases and cytologically positive pleural effusion. For a patient to be randomized, however, five additional criteria had to be met. First, the LCSG Pathology Reference Center had to confirm the diagnosis of pure small cell histology based on review of the diagnostic (prechemotherapy) material submitted for each case. There was ample time during the induction period for this to be done. Second, objective shrinkage of the tumor was required. So-called "stable disease" did not qualify. Third, all randomized patients must have received the identical induction treatment. Fourth, the patient's tumor had to be deemed resectable. The resectability assessment was made after response to chemotherapy. Superior vena cava syndrome, esophageal invasion, and pericardial effusion were unresectable conditions by definition. Otherwise, the resectability decision was a clinical one but had to be made prior to randomization. Finally, a repeated CT brain scan had to be normal, since the central nervous system sanctuary was not treated by the induction therapy. Randomization had to occur within 5 weeks of completion of chemotherapy. Following completion of all protocol treatment, patients were followed up at 3-month intervals and were subjected to clinical The primary statistical goal was to compare mortality rates for the surgery group vs the nonsurgical group. Sample size was determined by the number of patients needed to observe 90 deaths. Assuming proportional hazards for the two treatments and using the Mantel-Haenzel test, this provided a 90% probability of detecting a hazard ratio of 2 at the two-sided 0.05 significance level, which corresponds to a median survival of 30 months in the better group.13 All institutional and federal regulations concerning informed consent and peer judgment were fulfilled. Written consent was obtained from all patients who entered this study.
RESULTS
Over a 6-year period, 328 patients were registered in the preoperative induction phase of this trial. Sixty-five percent were male, 92% were white, and the median age was 59 years (range, 35 to 72 years). These demographic characteristics were evenly matched among the two randomized assignment groups and the nonrandomized group as well. The study census is shown in Table 1 . Two thirds of the registrants achieved at least a partial response, and two thirds of these were randomized (44% of the registered patients). Table 2 lists the reasons that one third of the responders were not randomized, and patient preference was a significant factor. Among the 146 randomized patients, 82% had a Karnofsky score of 9 or better, 92% had not lost more than 10% of their body weight, 40% had achieved a clinical complete response, and only 5% had residual disease greater than 5 cm2 in size. These clinical features describe a very favorable population and were equally balanced between the two treatment groups. The importance of a prospective randomized trial in assessing the virtues of a proposed innovation cannot be overemphasized. Furthermore, in this study, surgical resection and staging did not identify any subsets that appeared to benefit from its addition to multimodality therapy. Stage migration was observed, which is not surprising. "Salvage" surgery for non-small cell residual did not turn out to very successful, in contradistinction to a previous report.' 5 The statistical power of this study was not great despite the sizeable number of registrants. This fact underscores the select nature of the surgical candidates, who consisted of 44% of the total enrollment in the study. However, since the outcome favored the nonsurgical group with a 3-month median survival advantage, it is quite unlikely that the surgical group had a better result despite the type II error of the trial. In summary, the results of this study do not justify the inclusion of pulmonary resection in the multimodality strategy for treatment of small cell lung cancer.
The findings of this study do not address the true Tl NOMO small cell lesion, the peripheral nodule. Although such a lesion is quite rare, the diagnosis can be made by transthoracic fine needle aspiration cytology. As stated in the "Materials and Methods" section, these lesions were specifically excluded from the study. Surgical treatment of peripheral nodule small cell tumors is appropriate for two reasons. It is difficult to distinguish carcinoid tumors from small cell lung cancers by cytologic study and also a peripheral nodule small cell tumor is different from a garden-variety small cell lung cancer by its small size and peripheral location, suggesting a different biologic behavior. This has been recognized in the surgical literature for years. 3'4 
